Alzheimer’s disease: A matter of blood–brain barrier dysfunction?
Open accessThe DOI matches its Crossref record; 198 of the 200 references it cites were found in a registry or an index.
Abstract
The blood–brain barrier (BBB) keeps neurotoxic plasma-derived components, cells, and pathogens out of the brain. An early BBB breakdown and/or dysfunction have been shown in Alzheimer’s disease (AD) before dementia, neurodegeneration and/or brain atrophy occur. However, the role of BBB breakdown in neurodegenerative disorders is still not fully understood. Here, we examine BBB breakdown in animal models frequently used to study the pathophysiology of AD, including transgenic mice expressing human amyloid-β precursor protein, presenilin 1, and tau mutations, and apolipoprotein E, the strongest genetic risk factor for AD. We discuss the role of BBB breakdown and dysfunction in neurodegenerative process, pitfalls in BBB measurements, and how targeting the BBB can influence the course of neurological disorder. Finally, we comment on future approaches and models to better define, at the cellular and molecular level, the underlying mechanisms between BBB breakdown and neurodegeneration as a basis for developing new therapies for BBB repair to control neurodegeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CAA is caused by A 𝛃 deposition in the vascular wall of small brain arteries and capillaries and develops as a result of an imbalance between A 𝛃 production and clearance, particularly faulty transvascular and perivascular clearance of A 𝛃 from the brain (318, 420, 581, 640).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [420]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, microvascular endothelial aging also disrupts the blood-brain barrier, which promotes neuroinflammation, exacerbating cognitive decline”
From Single-cell RNA sequencing identifies senescent cerebromicrovascular endothelial cells in the aged mouse brain (2020) · cites this paper as Montagne et al. 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Loss of claudins is associated with BBB breakdown in human neurodegenerative disorders (155, 569) and acute CNS diseases (692), as well as in animal models of these diseases (420), as discussed below.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [420]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As previously reviewed, FDG-PET reflects mainly the transport activity of GLUT1 BBB transporter (420, 569).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [420]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Besides FDG-PET and verapamil-PET that have been used to test functions of BBB GLUT1 transporter and activity of ABCB1 (P-gp) efflux transporter in AD and PD (420, 569), respectively”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [420]
Experimental — accuracy not yet measured
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: Pericyte loss influences Alzheimer-like neurodegeneration in mice
Sagare, A. P., Bell, R. D., Zhao, Z., Ma, Q., Winkler, E. A., Ramanathan, A., & Zlokovic, B. V. (2013) · Nature Communications · doi:10.1038/ncomms3932 · Cited by 589
Self-citationRetractedSokoloff, L., Reivich, M., Kennedy, C., Rosiers, M. H. D., Patlak, C. S., Pettigrew, K. D., Sakurada, O., & Shinohara, M. (1977) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1977.tb10649.x · Cited by 6,000 · cited 6×
“…for glucose-6-phosphate isomerase and therefore cannot be converted into fructose-6-phosphate, a necessary step to enter the glycolytic pathway or Krebs cycle, as shown by multiple independent studies (Sols and Crane, 1954; Sokoloff et al., 1977; McDougal et al., 1990; Rokka et al., 2017).”
BackgroundInfluentialIliff, J. J., Wang, M., Liao, Y., Plogg, B. A., Peng, W., Gundersen, G. A., Benveniste, H., Vates, G. E., Deane, R., Goldman, S. A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003748 · Cited by 5,824
Wardlaw, J. M., Smith, E. E., Biessels, G. J., Cordonnier, C., Fazekas, F., Frayne, R., Lindley, R. I., O'Brien, J. T., Barkhof, F., Benavente, O. R., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70124-8 · Cited by 5,544 · cited 13×
“…in APPSw/0 mice (at 1, 3, and 6 mo of age; Ujiie et al., 2003; Paul et al., 2007; Sagare et al., 2013) before Aβ deposition, cerebral amyloid angiopathy (CAA), and/or behavioral deficits that develop later (at 7–10, 9–12, and 6–9 mo of age, respectively; Domnitz et al., 2005; Webster et al., 2014).”
BackgroundInfluentialSleep Drives Metabolite Clearance from the Adult Brain
Xie, L., Kang, H., Xu, Q., Chen, M. J., Liao, Y., Thiyagarajan, M., O’Donnell, J., Christensen, D. J., Nicholson, C., Iliff, J. J., et al. (2013) · Science · doi:10.1126/science.1241224 · Cited by 5,411
Structural and functional features of central nervous system lymphatic vessels
Louveau, A., Smirnov, I., Keyes, T. J., Eccles, J. D., Rouhani, S. J., Peske, J. D., Derecki, N. C., Castle, D., Mandell, J. W., Lee, K. S., et al. (2015) · Nature · doi:10.1038/nature14432 · Cited by 4,413
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210 · cited 1×
“Because of minimal glucose-6-phosphatase activity in the brain (Hers and De Duve, 1950; Sokoloff et al., 1977) and low 2DG-6P membrane permeability, 2DG-6P remains trapped in brain cells (Huang and Veech, 1985; Southworth et al., 2003) and is eliminated very slowly from the brain.”
BackgroundClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 2×
“, 2001; Armstrong, 2008) and imaging studies in the living human brain (Bateman et al., 2012; Benzinger et al., 2013; Fleisher et al., 2015), respectively.”
BackgroundOakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 1×
“…et al., 2002; Zipser et al., 2007; Hultman et al., 2013; Zonneveld et al., 2014; Halliday et al., 2016), diminished regional BBB uptake of glucose (Ossenkoppele et al., 2013; Protas et al., 2013), and early neurovascular dysfunction (Rei- man et al., 2004; Sheline et al., 2010; Thambisetty et…”
BackgroundHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · cited 1×
“3157JEM Vol. 214, No. 11 (PIC ALM) protein encoded by the PIC ALM gene, a highly validated genetic risk factor for human AD (Harold et al., 2009; Lambert et al., 2009; Huang et al., 2017), accelerates Aβ deposition in APPSw/0 mice, consistent with its critical role in regulating LRP1-mediated Aβ…”
Research works printed but not linked: 2
- Hachinski, 2016, Correction. World Stroke Organization. Stroke and potentially preventable dementias proclamation: updated World Stroke Day proclamation, Stroke., 47, e37
- Holtzman, 2000, Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer’s disease model, Ann. Neurol., 47, 739, 10.1002/1531-8249(200006)47:6<739::aid-ana6>3.0.co;2-8 · doi:10.1002/1531-8249(200006)47:6<739::aid-ana6>3.0.co;2-8
Cited by
Items 101–200 of 688
Magnetic Resonance Imaging of Blood–Brain Barrier permeability in Dementia
Chagnot, A., Barnes, S. R., & Montagne, A. (2021) · Neuroscience · doi:10.1016/j.neuroscience.2021.08.003 · Cited by 80
Self-citationEndothelial BACE1 Impairs Cerebral Small Vessels via Tight Junctions and eNOS
Zhou, H., Gao, F., Yang, X., Lin, T., Li, Z., Wang, Q., Yao, Y., Li, L., Ding, X., Shi, K., et al. (2022) · Circulation Research · doi:10.1161/circresaha.121.320183 · Cited by 88
Bryant, A. G., Li, Z., Jayakumar, R., Serrano‐Pozo, A., Woost, B., Hu, M., Woodbury, M. E., Wachter, A., Lin, G., Kwon, T., et al. (2023) · Journal of Neuroscience · doi:10.1523/jneurosci.0237-23.2023 · Cited by 88
“%) is consistent with findings that capillary endothelial cells comprise ;85% of the blood–brain barrier (Montagne et al., 2017).”
ResultNF-κB, a culprit of both inflamm-ageing and declining immunity?
Songkiatisak, P., Rahman, S. M. T., Aqdas, M., & Sung, M. (2022) · Immunity & Ageing · doi:10.1186/s12979-022-00277-w · Cited by 89
“Innate memory, albeit shorter-term than adaptive memory, may be constantly reinforced by elevated endotoxins leaking through the aged barriers, driving inflammaging at sites such as BBB, gut, and skin [68, 81].”
BackgroundAndersson, E., Janelidze, S., Lampinen, B., Nilsson, M., Leuzy, A., Stomrud, E., Blennow, K., Zetterberg, H., & Hansson, O. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.07.018 · Cited by 79
Ting, K. K., Coleman, P., Kim, H. J., Zhao, Y., Mulangala, J., Cheng, N. C., Li, W., Gunatilake, D., Johnstone, D. M., Loo, L., et al. (2023) · GeroScience · doi:10.1007/s11357-023-00927-x · Cited by 76
“Our results are consistent with previous reports describing BBB breakdown [77, 96, 97] and decreases in claudin-5 expression in human AD tissues and amyloidogenic models after significant plaque formation [56, 98].”
BackgroundResultHIV Neuroinfection and Alzheimer’s Disease: Similarities and Potential Links?
Canet, G., Dias, C., Gabelle, A., Simonin, Y., Gosselet, F., Marchi, N., Makinson, A., Tuaillon, E., Van de Perre, P., Givalois, L., et al. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00307 · Cited by 78
Limitations of human brain organoids to study neurodegenerative diseases: a manual to survive
Urrestizala-Arenaza, N., Cerchio, S., Cavaliere, F., & Magliaro, C. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1419526 · Cited by 80
“The neurovascular system is particularly important in neurodegeneration, thus blood–brain-barrier disruption, transcriptional changes in brain endothelial cells, and glymphatic system disruption cannot be studied in non-vascularized brain organoids (Montagne et al., 2017; Rasmussen et al., 2018).”
BackgroundVulnerability of the Hippocampus to Insults: Links to Blood–Brain Barrier Dysfunction
Davidson, T. L., & Stevenson, R. J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25041991 · Cited by 90
“Montagne and his collaborators [15,16] also used DCE-MRI to reveal a strong positive correlation between age and BBB permeability in the total hippocampus, the CA1 subfield, and the dentate gyrus of adult humans.”
BackgroundAge-Related Changes and Sex-Related Differences in Brain Iron Metabolism
Kezele, T. G., & Ćurko‐Cofek, B. (2020) · Nutrients · doi:10.3390/nu12092601 · Cited by 83
“The role of the BBB is to prevent the brain from neurotoxic plasma components and pathogens [102].”
BackgroundSmooth muscle cells of intracranial vessels: from development to disease
Frösén, J., & Joutel, A. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy002 · Cited by 84
Ullah, R., Park, T. J., Huang, X., & Kim, M. O. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101451 · Cited by 78
“DM-accompanied with hyperglycemia might cause BBB disruption that in turn impedes Aβ peptide clearance, as shown in mouse brain (Montagne et al., 2017; Salameh et al., 2016).”
Transport Across the Blood-Brain Barrier
Fu, B. M., & Akli, L. F. A. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-032-22285-5_15 · Cited by 87
Neurovascular Alterations in Vascular Dementia: Emphasis on Risk Factors
Lecordier, S., Manrique‐Castano, D., Moghrabi, Y. E., & ElAli, A. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.727590 · Cited by 80
Modulation of the Blood–Brain Barrier for Drug Delivery to Brain
Han, L. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122024 · Cited by 71
Alexandrov, P., Zhai, Y., Li, W., & Lukiw, W. (2019) · Folia Neuropathologica · doi:10.5114/fn.2019.88449 · Cited by 72
“Recent experimental evidence continues to support the idea that the GI-tract microbiome is capable of providing a rich source of potentially neurotoxic mediators capable of crossing the age-compromised or diseased GI-tract endothelial cell barriers into the systemic circulation and then transit the BBB into the brain…”
BackgroundInfluentialJeon, M.-T., Kim, K.-S., Kim, E. S., Lee, S., Kim, J., Hoe, H.-S., & Kim, D.-G. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101333 · Cited by 76
“Importantly, BBB disruption is observed in all of the numerous mouse models of AD, including 5xFAD mice (Montagne et al., 2017), and breakdown of the BBB precedes plaque formation (Ujiie et al.”
BackgroundParodi-Rullán, R. M., Javadov, S., & Fossati, S. (2021) · Cells · doi:10.3390/cells10112903 · Cited by 73
Ponce-Lopez, T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094209 · Cited by 75
“The observed discrepancies may be due to variations in the techniques used to assess BBB permeability, the specific animal models employed, and the stage of disease progression examined [390].”
Park, J. S., Choe, K., Khan, A., Jo, M. H., Park, H. Y., Kang, M. H., Park, T. J., & Kim, M. O. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065283 · Cited by 78
McConnell, H., Li, Z., Woltjer, R. L., & Mishra, A. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.04.005 · Cited by 83
“Indeed, loss of BBB integrity is common in animal models of AD (Montagne et al., 2017), and blood constituents such as albumin, fibrinogen and immunoglobulins accumulate in aging human brains (Goodall et al.”
BackgroundLukiw, W. J. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00022 · Cited by 74
Oxidative Stress and the Neurovascular Unit
Rinaldi, C., Donato, L., Alibrandi, S., Scimone, C., D’Angelo, R., & Sidoti, A. (2021) · Life · doi:10.3390/life11080767 · Cited by 79
d’Abramo, C., D'adamio, L., & Giliberto, L. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030116 · Cited by 78
SARS-CoV-2: is there neuroinvasion?
McQuaid, C., Brady, M., & Deane, R. (2021) · Fluids and Barriers of the CNS · doi:10.1186/s12987-021-00267-y · Cited by 74
Xu, L., Li, C., Wan, T., Sun, X., Lin, X., Yan, D., Li, J., & Wei, P. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-024-01965-4 · Cited by 78
Wang, L., Shi, Y., Jiang, J., Li, C., Zhang, H., Zhang, X., Jiang, T., Wang, L., Wang, Y., & Feng, L. (2022) · Small · doi:10.1002/smll.202203678 · Cited by 71
Gadhave, K., Kumar, D., Uversky, V. N., & Giri, R. (2021) · Medicinal Research Reviews · doi:10.1002/med.21719 · Cited by 68
“The BBB regulates the homeostasis of the CNS by controlling the molecular exchange between the brain parenchyma and blood flow and keeps neurotoxic plasma‐derived components, pathogens, and cells out of the brain.(403) Leakage of the BBB leads to an influx of cells, microbial pathogens, and neurotoxic blood‐derived de…”
BackgroundTherapeutic non-invasive brain treatments in Alzheimer’s disease: recent advances and challenges
Wu, C., Yang, L., Feng, S., Zhu, L., Yang, L., Liu, T. C.-Y., & Duan, R. (2022) · Inflammation and Regeneration · doi:10.1186/s41232-022-00216-8 · Cited by 72
“Another study found that PBM could promote the permeability of BBB, which results in increased Aβ leakage followed by further activation of the lymphatic clearance of Aβ [111].”
BackgroundResultInfluentialDysregulated Wnt Signalling in the Alzheimer’s Brain
Aghaizu, N. D., Jin, H., & Whiting, P. J. (2020) · Brain Sciences · doi:10.3390/brainsci10120902 · Cited by 70
“Indeed, BBB disruptions are a key feature of AD, bringing about increased BBB permeability leading to CNS microbleeding and perivascular infiltration of neurotoxic blood-derived products, cellular infiltration and degeneration of pericytes and ECs, as well as impaired GLUT-1 and P-gp function, which negatively impact…”
BackgroundSex-Related Differences in Regional Blood–Brain Barrier Integrity in Non-Demented Elderly Subjects
Moon, Y., Lim, C., Kim, Y., & Moon, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062860 · Cited by 74
“Moreover, by using neuroimaging analysis, it is possible to reveal discrete regional changes [3,6,8,9,16].”
BackgroundMethodWiȩckowska-Gacek, A., Mietelska-Porowska, A., Chutorański, D., Wydrych, M., Długosz, J., & Wojda, U. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.654509 · Cited by 71
Uchida, Y., Kan, H., Sakurai, K., Oishi, K., & Matsukawa, N. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1111448 · Cited by 88
The leukotriene signaling pathway: a druggable target in Alzheimer’s disease
Michael, J., Marschallinger, J., & Aigner, L. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.09.008 · Cited by 75
“Alterations and loss of tight junction proteins [77], as well as pericyte degeneration [76], might lead to BBB disruption at the capillary level.”
BackgroundNeurovascular unit dysfunction as a mechanism of seizures and epilepsy during aging
van Vliet, E. A., & Marchi, N. (2022) · Epilepsia · doi:10.1111/epi.17210 · Cited by 71
Tau immunotherapies for Alzheimer’s disease
Hoskin, J. L., Sabbagh, M. N., Al-Hasan, Y., & Decourt, B. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1619694 · Cited by 68
“However, it is important to note that the BBB is often compromised in AD [64], thus it is likely that antibodies can act directly on brain tissue in such condition.”
BackgroundGiorgi, F. S., Galgani, A., Puglisi‐Allegra, S., Limanaqi, F., Busceti, C. L., & Fornai, F. (2020) · Journal of Neuroscience Research · doi:10.1002/jnr.24718 · Cited by 63
Role of P2X7 Receptors in Immune Responses During Neurodegeneration
Oliveira-Giacomelli, Á., Petiz, L. L., Andrejew, R., Turrini, N., Silva, J. B., Sack, U., & Ulrich, H. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.662935 · Cited by 68
Peripheral and Central Nervous System Immune Response Crosstalk in Amyotrophic Lateral Sclerosis
Liu, Z., Cheng, X., Zhong, S., Zhang, X., Liu, C., Liu, F., & Zhao, C. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00575 · Cited by 65
Moon, W.-J., Lim, C., Ha, I. H., Kim, Y., Moon, Y., Kim, H.-J., & Han, S.-H. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20952012 · Cited by 66
“We aimed to evaluate BBB permeability changes in patients with MCI and normal controls, and hypothesized that increased BBB permeability would follow either the anatomical pattern of common microvascular pathology (white matter) or AD-specific tau pathology (hippocampus, inferior temporal gyrus) or amyloid pathology (…”
MethodInfluentialReconsidering the role of blood-brain barrier in Alzheimer’s disease: From delivery to target
Sousa, J. A., Bernardes, C., Bernardo-Castro, S., Lino, M. M., Albino, I., Ferreira, L., Brás, J., Guerreiro, R. J., Tábuas‐Pereira, M., Baldeiras, I., et al. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1102809 · Cited by 71
Núñez, C., Stephan-Otto, C., Usall, J., Bioque, M., Lobo, A., González-Pinto, A., Pina-Camacho, L., Vieta, E., Castro-Fornieles, J., Rodriguez-Jimenez, R., et al. (2019) · Schizophrenia Bulletin · doi:10.1093/schbul/sby113 · Cited by 68
Linking APOE-ε4, blood-brain barrier dysfunction, and inflammation to Alzheimer's pathology
Riphagen, J. M., Ramakers, I. H. G. M., Freeze, W. M., Pagen, L. H. G., Hanseeuw, B. J., Verbeek, M. M., Verhey, F. R. J., & Jacobs, H. I. L. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.09.020 · Cited by 65
Annexin A1 restores cerebrovascular integrity concomitant with reduced amyloid-β and tau pathology
Ries, M., Watts, H. R., Mota, B. C., Lopez, M. Y., Donat, C. K., Baxan, N., Pickering, J. A., Chau, T. W., Semmler, A., Gurung, B., et al. (2021) · Brain · doi:10.1093/brain/awab050 · Cited by 68
“Damaged blood vessels and blood–brain barrier breakdown were initially associated with amyloid-b and tau pathology in animal models.(4,5) More recently, these alterations were observed in individuals with early cognitive dysfunction regardless of amyloid-b or tau markers.”
BackgroundPlasma lipid peroxidation biomarkers for early and non-invasive Alzheimer Disease detection
Peña-Bautista, C., Vigor, C., Galano, J.-M., Oger, C., Durand, T., Ferrer, I., Cuevas, A., López-Cuevas, R., Baquero, M., López-Nogueroles, M., et al. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.06.038 · Cited by 66
Sleep and circadian rhythm disruption and stress intersect in Alzheimer's disease
Phan, T. X., & Malkani, R. G. (2019) · Neurobiology of Stress · doi:10.1016/j.ynstr.2018.10.001 · Cited by 60
“Breakdown of the BBB – a finding consistently observed in people with AD (Zlokovic, 2011) – can be detected before any symptomatic onset of cognitive impairment and any AD pathology in the brain (Montagne et al., 2017) and even before changes in cerebrospinal fluid Aβ and tau levels (Montagne et al.”
Cao, Y., Zhao, L.-W., Chen, Z.-X., & Li, S.-H. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1430465 · Cited by 65
“BBB dysfunction manifests in the early stages of AD, irrespective of changes in A β or tau biomarkers (Montagne et al., 2017; Nation et al., 2019).”
BackgroundFaridar, A., Vasquez, M., Thome, A. D., Yin, Z., Xuan, H., Wang, J. H., Wen, S., Li, X., Thonhoff, J. R., Zhao, W., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01447-z · Cited by 71
3K3A-activated protein C blocks amyloidogenic BACE1 pathway and improves functional outcome in mice
Lazic, D., Sagare, A. P., Nikolakopoulou, A. M., Griffin, J. H., Vassar, R., & Zlokovic, B. V. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20181035 · Cited by 65
A Leaky Blood–Brain Barrier to Fibrinogen Contributes to Oxidative Damage in Alzheimer’s Disease
McLarnon, J. G. (2021) · Antioxidants · doi:10.3390/antiox11010102 · Cited by 69
“Overall, the mechanisms linking BBB leakiness to fibrinogen with neuronal and synaptic dysfunction are not well understood [1,32,60].”
BackgroundExercise mimetics: a novel strategy to combat neuroinflammation and Alzheimer’s disease
Zhao, R. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03031-9 · Cited by 66
“BBB dysfunction is a key feature of AD pathology [202, 203]; it affects Aβ clearance, endothelial and pericyte function, tight junction integrity, and microglia activation of the brain [203–205].”
BackgroundLiao, J., He, W., Li, L., Wang, J., Gong, L., Zhang, Q., & Lin, Z. (2025) · Cell Biomaterials · doi:10.1016/j.celbio.2025.100016 · Cited by 77
Chernick, D., Ortiz-Valle, S., Jeong, A., Qu, W., & Li, L. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134306 · Cited by 62
Advances on fluid shear stress regulating blood-brain barrier
Wang, X., Xu, B., Xiang, M., Yang, X., Liu, Y., Liu, X., & Shen, Y. (2019) · Microvascular Research · doi:10.1016/j.mvr.2019.103930 · Cited by 67
Beyond barrier functions: Roles of pericytes in homeostasis and regulation of neuroinflammation
Bhattacharya, A., Kaushik, D. K., Lozinski, B. M., & Yong, V. W. (2020) · Journal of Neuroscience Research · doi:10.1002/jnr.24715 · Cited by 62
Ferrari, F., Moretti, A., & Villa, R. F. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108277 · Cited by 59
Liu, Y., Huber, C. C., & Wang, H. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.02.074 · Cited by 62
Poustforoosh, A., Nematollahi, M. H., Hashemipour, H., & Pardakhty, A. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.015 · Cited by 63
ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease
Li, Y., Macyczko, J. R., Liu, C.-C., & Bu, G. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.03.011 · Cited by 61
Kochman, U., Sitka, H., Kuźniar, J., Czaja, M., Kozubek, P., Beszłej, J. A., & Leszek, J. (2026) · Molecular Neurobiology · doi:10.1007/s12035-025-05417-z · Cited by 60
Liu, X., Naomi, S. S. M., Sharon, W. L., & Russell, E. J. (2021) · Aging and disease · doi:10.14336/ad.2021.0510 · Cited by 52
“Numerous animal and postmortem human studies have confirmed BBB breakdown takes place in the AD brain, which exhibits extravascular leakage, pericyte and endothelial degeneration, as well as loss of BBB tight junctions [65, 66].”
BackgroundAlzheimer’s disease pathogenesis: standing at the crossroad of lipid metabolism and immune response
Wang, Z., Zhang, L., & Qin, C. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00857-6 · Cited by 65
“Vascular dysfunction is a major risk factor for neurological diseases, with early blood-brain barrier (BBB) disruption and/or dysfunction in AD often observed before the onset of dementia, neurodegeneration, or brain atrophy [159, 160].”
Shen, W., Elahi, M., Logue, J., Yang, P., Baracco, L., Reece, E. A., Wang, B., Li, L., Blanchard, T. G., Han, Z., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.31.478476 · Cited by 64
“In addition to olfactory transmucosal entry of 66 SARS-CoV-2 into the central nervous system (CNS) [8], other potential routes of SARS-CoV-2 brain 67 entry, including blood–brain barrier (BBB) passage, especially under conditions of a compromised BBB, 68 such as in cases of Alzheimer’s disease and autism [12, 13], and…”
BackgroundA New Hypothesis for Alzheimer’s Disease: The Lipid Invasion Model
Rudge, J. D. (2022) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-210299 · Cited by 58
Increased plasma bradykinin level is associated with cognitive impairment in Alzheimer's patients
Singh, P. K., Chen, Z., Ghosh, D., Strickland, S., & Norris, E. H. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104833 · Cited by 66
Montagne, A., Barnes, S. R., Nation, D. A., Kisler, K., Toga, A. W., & Zloković, B. V. (2022) · GeroScience · doi:10.1007/s11357-022-00571-x · Cited by 63
Self-citationCheon, S. Y., & Song, J. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00836-0 · Cited by 61
“Changes in vascular territories, such as loss of vascular integrity, vascular malfunction, and BBB disruption, are observed in patients with AD [57].”
BackgroundProgress in Target Drug Molecules for Alzheimer's Disease
Xie, J., Liang, R., Wang, Y., Huang, J., Cao, X., & Niu, B. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666191203113745 · Cited by 60
Sah, E., Krishnamurthy, S., Ahmidouch, M. Y., Gillispie, G. J., Milligan, C., & Orr, M. E. (2021) · Life · doi:10.3390/life11030229 · Cited by 55
Mesenchymal stromal cells for the treatment of Alzheimer’s disease: Strategies and limitations
Regmi, S., Liu, D. D., Shen, M., Kevadiya, B. D., Ganguly, A., Primavera, R., Chetty, S., Yarani, R., & Thakor, A. S. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1011225 · Cited by 51
“Downregulated glucose transport to the brain during AD progression also accelerates BBB breakdown and Aβ pathology, since the loss of glucose contributes to an energy deficiency that induces neuron necrosis and the resulting neuroinflammation (Nelson et al., 2016; Montagne et al., 2017).”
BackgroundAdult neurogenesis in Alzheimer's disease
Choi, S. H., & Tanzi, R. E. (2023) · Hippocampus · doi:10.1002/hipo.23504 · Cited by 61
“Activated astrocytes and microglia as well as disrupted vasculature are evident in AD (Bartels et al., 2020; Chun & Lee, 2018; Mandrekar-Colucci & Landreth, 2010; Montagne et al., 2017; Price et al., 2021; Sweeney et al., 2018).”
BackgroundAlcohol as a Modifiable Risk Factor for Alzheimer’s Disease—Evidence from Experimental Studies
Chandrashekar, D. V., Steinberg, R. A., Han, D., & Sumbria, R. K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119492 · Cited by 56
“BBB dysfunction and breakdown can contribute to AD pathology and cognitive decline via different mechanisms, including a reduction in brain perfusion, alteration in the function and expression of BBB transporters and receptors, an infiltration of peripheral blood-derived products and neurotoxins, neuroinflammatory and…”
BackgroundResultİş, Ö., Wang, X., Reddy, J. S., Min, Y., Yılmaz, E., Bhattarai, P., Patel, T., Bergman, J., Quicksall, Z., Heckman, M. G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48926-6 · Cited by 66
“Both of these genes were signi fi cantly upregulated in AD brains in the pericyte cl.25 and had strong interactions with astrocyte ligands, some of which are known AD risk genes, namely APOE , APP , PSEN1 and MAPT , previously showntoleadtoBBBdysfunctionin modelsystems 92 .”
Maitre, Y., Mahalli, R., Micheneau, P., Delpierre, A., Amador, G., & Denis, F. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182111157 · Cited by 61
“Although alterations in the BBB have been found both in AD patients and in animal models, their role in the disease process remains unclear [74].”
Dean, T., Mendiola, A. S., Yan, Z., Meza-Acevedo, R., Cabriga, B., Akassoglou, K., & Ryu, J. K. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03092-w · Cited by 57
“Understanding sex-specific immune responses will further provide insights into TBI pathophysiology and its long-term consequences, including the potential development of dementia [42].”
BackgroundLuo, C., Pi, X., Hu, N., Wang, X., Xiao, Y., Li, S., Sweeney, J. A., Bishop, J. R., Gong, Q., Xie, D., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01308-6 · Cited by 55
Liu, Y., Zhuang, D., Wang, J., Huang, H., Li, R., Wu, C., Deng, Y., Hu, G., & Guo, B. (2022) · The Analyst · doi:10.1039/d2an01327d · Cited by 54
Shi, H., Koronyo, Y., Fuchs, D.-T. S., Sheyn, J., Jallow, O., Mandalia, K., Graham, S. L., Gupta, V., Mirzaei, M., Kramerov, A. A., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13086 · Cited by 53
T cell infiltration mediates neurodegeneration and cognitive decline in Alzheimer's disease
Zeng, J., Liao, Z., Yang, H., Wang, Q., Wu, Z., Hua, F., & Zhou, Z. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106461 · Cited by 55
Kisler, K., Lazić, D., Sweeney, M. D., Plunkett, S., Khatib, M. E., Vinogradov, S. A., Boas, D. A., Sakadžić, S., & Zloković, B. V. (2018) · Nature Protocols · doi:10.1038/nprot.2018.034 · Cited by 58
Zhao, Q., Dai, W., Chen, H. Y., Jacobs, R. E., Zlokovic, B. V., Lund, B. T., Montagne, A., & Bonnin, A. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2113310119 · Cited by 52
Self-citationEngineered 3D human neurovascular model of Alzheimer's disease to study vascular dysfunction
Pavlou, G., Spitz, S., Pramotton, F. M., Tsai, A., Li, B. M., Wang, X., Barr, O. M., Ko, E. C., Zhang, S., Ashley, S. J., et al. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122864 · Cited by 53
Wyatt-Johnson, S. K., & Brutkiewicz, R. R. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.592359 · Cited by 50
Shao, X., Shou, Q., Felix, K., Ojogho, B., Jiang, X., Gold, B. T., Herting, M. M., Goldwaser, E. L., Kochunov, P., Hong, E. L., et al. (2024) · eLife · doi:10.7554/elife.96155.3 · Cited by 58
Sharma, A., Smith, M. A., Muresanu, D. F., Dey, P. K., & Sharma, H. S. (2019) · International review of neurobiology · doi:10.1016/bs.irn.2019.06.005 · Cited by 52
Huang, N., Huang, Y., Deng, Z., Qi, S., Zhang, W., Liu, Y., & Tan, G. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5577 · Cited by 53
“Under physiological conditions, the BBB acts as a protective barrier, preventing the entry of neurotoxic plasma components, blood cells and pathogens into the brain (165).”
VEGF receptor‐1 modulates amyloid β 1–42 oligomer‐induced senescence in brain endothelial cells
Angom, R. S., Wang, Y., Wang, E., Pal, K., Bhattacharya, S., Watzlawik, J. O., Rosenberry, T. L., Das, P., & Mukhopadhyay, D. (2018) · The FASEB Journal · doi:10.1096/fj.201802003r · Cited by 53
Circadian regulation of astrocyte function: implications for Alzheimer’s disease
McKee, C. A., Lananna, B. V., & Musiek, E. S. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03314-y · Cited by 51
A human brain vascular atlas reveals diverse cell mediators of Alzheimer’s disease risk
Yang, A. C., Vest, R. T., Kern, F., Lee, D. P., Maat, C. A., Losada, P. M., Chen, M. B., Agam, M., Schaum, N., Khoury, N., et al. (2021) · doi:10.1101/2021.04.26.441262 · Cited by 48
Yue, Q., Leng, X., Xie, N., Zhang, Z., Yang, D., & Hoi, M. P. M. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70079 · Cited by 48
Gao, C., Shen, X., Tan, Y., & Chen, S. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02580-1 · Cited by 51
“Breakdown of the BBB and increased permeability have been observed in patients with AD and the disruption of BBB correlates with disease progression [172].”
BackgroundVascular Dementia: From Pathophysiology to Therapeutic Frontiers
Yang, H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14186611 · Cited by 51
A Review of Application of Aβ42/40 Ratio in Diagnosis and Prognosis of Alzheimer’s Disease
Xu, C., Zhao, L., & Dong, C. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220673 · Cited by 48
“As one of the few proteins related to AD neuropathology that can penetrate the blood—brain barrier [88], plasma A (cid:2) is considered to be a metabolic byproduct of brain-derived amyloid plaques, and the establishment of new technology has made it possible to take plasma A (cid:2) as a surrogate…”
Petralla, S., Panayotova, M., Franchina, E., Fricker, G., & Puris, E. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16070948 · Cited by 49
“CAA can cause microbleeds in the brain, which were found to be increased in patients with early-stage dementia, AD patients and APOE4 carriers [52–56] as well as various mouse models of AD [57–59].”
BackgroundMicrobiome-Mediated Upregulation of MicroRNA-146a in Sporadic Alzheimer’s Disease
Zhao, Y., & Lukiw, W. J. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00145 · Cited by 47
Blood-Brain Barrier Dysfunction in Idiopathic Intracranial Hypertension
Hasan‐Olive, M. M., Hansson, H., Enger, R., Nagelhus, E. A., & Eide, P. K. (2019) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlz063 · Cited by 49
Kok, F. K., van Leerdam, S., & de Lange, E. C. M. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-210607 · Cited by 46
“This 527 BBB breakdown results in leakage throughout the 528 cerebrum, due to dilatation of the BBB’s tight junc529 tions [134].”
BackgroundAlzheimer’s Disease: A Systems View Provides a Unifying Explanation of Its Development
Grobler, C., van Tongeren, M., Gettemans, J., Kell, D. B., & Pretorius, E. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220720 · Cited by 51
“BBBdamageinAD iswellestablishedinresearch[221].”
APOE 𝜀4‐related blood–brain barrier breakdown is associated with microstructural abnormalities
Reas, E. T., Solders, S. K., Tsiknia, A. A., Triebswetter, C., Shen, Q., Rivera, C. S., Andrews, M., Alderson‐Myers, A., & Brewer, J. B. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14302 · Cited by 46
Endothelins in inflammatory neurological diseases
D’Orléans-Juste, P., Ndunge, O. B. A., Desbiens, L., Tanowitz, H. B., & Desruisseaux, M. S. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.10.001 · Cited by 46
Metadata
- Authors
- Montagne, A., Zhao, Z., & Zlokovic, B. V.
- Affiliations
- University of Southern California (US)
- Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, Los Angeles, CA 1
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2017-10-23
- Volume
- 214
- Issue
- 11
- Pages
- 3151-3169
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC5679168
- OpenAlex
- W2766949297
- Cited by
- 672
- References
- 200
- Citations by year
- 2026: 54 · 2025: 56 · 2024: 93 · 2023: 82 · 2022: 82 · 2021: 90 · 2020: 91 · 2019: 76 · 2018: 46 · 2017: 2
- FWCI
- 5.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (R01AG023084, R01NS090904, R01NS034467, R01AG039452, 5P01AG052350)
- Cure for Alzheimer’s Fund
- Alzheimer’s Association
- Fondation Leducq (16 CVD 05)
- Topics
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- Alzheimer's disease, blood-brain barrier dysfunction, blood-brain barrier disruption, neurodegeneration, amyloid precursor protein, presenilin 1, tau mutations, apolipoprotein E, transgenic mouse model, BBB repair
- MeSH terms
- Alzheimer Disease, Animals, Blood-Brain Barrier, Disease Models, Animal, Humans, Mice, Transgenic, Mutation, Amyloid beta-Protein Precursor, tau Proteins, Presenilin-1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.